Jun 22, 2020
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
Oct 08, 2019
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
Jul 11, 2019
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
Jul 11, 2019
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Jul 10, 2019
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
Jun 18, 2019
The BRAF kinase inhibitors market will register a CAGR of over 8% by 2023
Jun 17, 2019
Pfizer to Acquire Array BioPharma
May 29, 2019
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
May 16, 2019
Blood Test Can Measure Effectiveness of Treatments for Aggressive Skin Cancers
Jan 03, 2019
REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019
Nov 28, 2018
Sentinel Biomedical launches new non-invasive laboratory analysis
Aug 14, 2018
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Apr 30, 2018
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Apr 20, 2018
Global Melanoma Market Report 2018 - Anticipated to Reach a Market Value of $14 Billion by 2024
Jan 20, 2018
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
Dec 22, 2017
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Nov 06, 2017
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
Oct 30, 2017
Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim's BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
Sep 10, 2017
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Sep 08, 2017
Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress